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INTRODUCTION 
Solid lipid nanoparticles and nanostuctured lipid carriers 
have attracted much attention in the last decade in 
transdermal drug delivery. Solid lipid nanoparticles 
(SLNs) are identical to an oil-in-water emulsion wherein 
the liquid lipid (oil) of the emulsion has been replaced 
by a solid lipid that has a liquid- to-solid phase transition 
well above the body temperature (37°C).
1
 SLNs are 
colloidal particles containing highly purified 
triglycerides, composed mainly of lipids that are solid at 
room temperature and further stabilized by surfactants.
2
 
SLNs are produced by one of the following techniques
3
, 
viz. High Pressure Homogenization, High Shear 
Homogenization, Microemulsion Templates, Solvent 
Injection Method employing water-insoluble solvent, 
and Solvent Emulsification Diffusion method using a 
partially water-miscible solvent
4
.To overcome some of 
the limitations of SLNs, viz. limited drug loading and 
drug leakage during storage, nanostructured lipid 
carriers (NLC) have been developed. They consist of a 
solid lipid matrix with a high content of liquid lipid. 
These carriers are composed of physiological and 
biodegradable lipid, exhibiting low systemic toxicity and 
low cytotoxicity
5
. The small size of lipid particles ensure 
close contact to the stratum corneum and can enhance 
drug flux through the skin, and due to their solid lipid 
matrix, a controlled release from these carriers are 
possible.
 6
 
Etoricoxib is a nonsteroidal anti-inflammatory drug that 
acts by inhibition of cycloxygenase II (COX-II) and is 
used in the treatment of inflammation and arthritis. An 
arthritic condition demands a controlled-release drug 
delivery system for a prolonged period to satisfy the 
goals of treatment like reducing pain and inflammation, 
slowing disease progression, and preventing adverse 
reactions. Therefore the aim of the study was to design 
Etoricoxib loaded Nanostructured lipid carrier (NLCs) 
gel for topical delivery that could not only increase 
delivery of drug locally and improve the release of the 
drug for a prolonged period, but also reduce the risk of 
gastrointestinal side effects and toxicity. 
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ABSTRACT 
Nanostructured lipid carriers (NLC)-based topical gel of Etoricoxib was prepared with the aim for the treatment of 
inflammation and allied conditions.  The composition of NLC consisted of Stearic acid as solid lipid, oleic acid as liquid 
lipid and tween 80 as a surfactant. NLCs prepared by melt-emulsification and low temperature solidification techniques 
were characterized by particle sizing technology, scanning electron microscopy (SEM), and differential scanning 
calorimetry (DSC). All of the NLC showed high entrapment efficiency ranging from 69% to 76%. Both the entrapment and 
release rate were affected by the percentage of oleic acid. NLC-F3G-C was selected as best formulation with average 
particle size of 244 nm and polydispersity index of 0.690 indicating homogeneity in particle size distribution. The higher 
magnitude of zeta potential of NLC-F3G-C indicates the stability of formulation. The nanoparticulate dispersion was 
suitably gelled and assessed for Physical appearance, Homogeneity, Spreadability and in-vitro permeation study. In-vitro 
drug release pattern of developed NLC dispersion gel showed burst and prolong release. It was concluded that developed 
NLC gel of Etoricoxib holds promise for prolonged availability of drug in the skin tissues and can be used for better 
management of inflammatory conditions. 
Keywords: Etricoxib • Nanostructured lipid carriers (NLC) • Topical gel • Nanoparticle   
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MATERIALS AND METHODS 
MATERIALS 
Etoricoxib was obtained as a gift from Unison 
Pharmaceuticals, Baddi, India. Carbopol 940 was a kind 
gift sample from Guapha Pharmaceuticals, INDIA. 
Stearic acid, Oleic acid & Glycerol were purchased from 
Fizmerk India chemicals, Hapur (U.P), INDIA. All other 
chemicals were of analytical grade. 
Solubility Study 
The solubility of Etoricoxib was determined in distilled 
water and Phosphate buffer solutions of pH 4.0, 5.0, 6.0, 
6.4, 6.8, 7.0, 7.2, 7.4, 7.6. An excess amount of drug was 
added to 10ml of different solvent. The contents were 
stirred continuously for 24 hours at 37
0
C and allowed to 
equilibrate. After 24 hours the sample were withdrawn 
and filtered through membrane filter and the filtrate 
were suitably diluted with an appropriate solvent and 
analyzed spectrophotometrically (UV-1371, electronical 
India, INDIA) for Etoricoxib concentrations, at 233 nm 
with reference to a corresponding calibration curve. 
Each experiment was done in triplicate and the 
equilibrium solubility was recorded.
7, 8 
Partition Coefficient Study 
Equal volumes of distilled water , buffer solutions of pH 
4.0, 5.0, 6.0, 6.4, 6.8, 7.2, 7.4, 7.6 and isopropyl 
myristate (IPM) were previously saturated with each 
other by shaking together in shaker for 3 hours and the 
two phases were left to separate overnight. To each of 
the separated IPM phases, a known concentration of 
Etoricoxib was added with gentle shaking until 
dissolved. The mixtures were then agitated for 6 hours at 
room temperature, and the two phases were left to 
separate again. The drug concentration in aqueous 
phases was determined spectrophotometrically at 233 
nm, after suitable dilution. The results, treated according 
to Equation.
 9
 
 
Preparation of NLC Dispersion 
Melt emulsification and low-temperature 
Solidification method: Etoricoxib was dissolved in 
methanol and mixed with acetone solution containing 
blend of stearic acid and oleic acid (SA+OA). The 
mixture was sonicated for 15 minute, and then added 
drop wise to tween 80 solutions, stirred at 3000 rpm 
using magnetic stirrer (Remi instruments Ltd.,Mumbai, 
India) for 30 min at 70
0
C temperature. The mixed 
solution was transferred to icy water bath and stirred for 
four hour at 3000 rpm. The NLC dispersions were 
lyophilized for further study.
 10
The formulations 
variables are tabulated in table 1. 
 
Table 1: Composition of different NLC dispersion (batch size 100g)
 
 
 
 
 
 
 
Characterization of NLC Dispersion 
Particle size and Polydispersity Index Distribution 
Particle size and polydispersity index (PI) which is a 
measure of the distribution of nanoparticle population 
were determined by using Malvern Mastersizer 
2000MU (Malvern instrument UK detection limit 0.01–
1,000 μm). The obtained data were evaluated using the 
volume distribution (d10%, d50%, d90%) which means that 
if the diameter 90% (d90%) is registered as 1 μm, this 
indicates that 90% of particles have a diameter of 1 μm 
or lower. The PI was measured by the span which can 
be calculated from the following equation. 
Where d90% is the particle diameter at 90% cumulative 
size, d10% is the particle diameter at 10% cumulative 
size, and d50% is the particle diameter at 50% cumulative 
size.
 11 
 
Zeta Potential (ζ) 
The zeta potential was measured by using the Zetasizer 
2000 (Malvern Instruments, UK). Zeta potential is the 
electric potential of a particle in a suspension. It is a 
parameter which is very useful for the assessment of the 
physical stability of colloidal dispersions. In suspensions 
the surfaces of particles develop a charge due to 
ionization of surface groups or adsorption of ions. This 
charge depends on both the surface chemistry of the 
particles and the media around these particles.  
Scanning Electron Microscopy 
The morphological characteristicsof NLC was studied 
by scanning electron microscope (JEOL-JSM-6360 
JAPAN). One drop of sample was placed on a slide and 
excess water was left to dry at room temperature. 
Further the slide was attached to the specimen holder 
using a double coated adhesive tape and gold coated 
under vacuum using a sputter coater (Model JFC-1100, 
Jeol, JAPAN)for 10 minute and investigated at 20kV.
12 
Drug entrapment efficiency and drug loading 
determination 
Formulation 
Code 
Lipid Tween 80 Drug Water Final 
Amount Stearic acid Oleic acid 
BLANK 0.9g 0.1g 2.5g NIL 96.4g 100g 
NLC-F1 0.9g 0.1g 2.5g 0.1g 96.5g 100g 
NLC-F2 0.8g 0.2g 2.5g 0.1g 96.4g 100g 
NLC-F3 0.7g 0.3g 2.5g 0.1g 96.4g 100g 
Sachan et al                                        Journal of Drug Delivery & Therapeutics. 2016; 6(2):4-13 6 
© 2011-16, JDDT. All Rights Reserved                                   ISSN: 2250-1177                               CODEN (USA): JDDTAO 
A volume of 2.0 ml of each drug-loaded sample was 
centrifuged at 12500 rpm for 45 min to separate the lipid 
and aqueous phase. The supernatant was then diluted 
with methanol and analyzed by UV-VIS 
spectrophotometer (UV-1800 Shimadzu 
spectrophotometer) at 233 nm. The entrapment efficacy 
of nanoparticles was calculated as follows: 
 
 
Where EE is entrapment efficiency, DL is Drug loading, 
Wa stands for the mass of Etoricoxib added to the 
formulation and Ws is the analyzed weight of drug in 
supernatant and Wl is weight of lipid added.
 13, 14, 15
 
 Infra-red spectroscopy 
An IR spectrum reveals the characteristic peaks of all 
functional groups present in a sample. In order to 
ascertain successful entrapment, the drug, lipid, their 
physical mixture and NLC were subjected to FTIR 
studies. IR spectra of Etoricoxib (ETORI), stearic acid 
(SA),  physical mixture of stearic acid and oleic acid 
(SA+OA), blank NLC and  etoricoxib loaded NLC 
formulation were recorded using IR 
Spectrophotometer(Shimadzu model 8400) between the 
range of 500 cm
-1 to
 4000 cm
-1
. 
Thermal analysis 
Differential Scanning Calorimeter Analysis (DSC) 
DSC analysis of Etoricoxib (ETORI), stearic acid (SA), 
physical mixture of stearic acid and oleic acid 
(SA+OA), and NLC formulation were performed using 
Perkin-Elmer DSC model. The instrument was 
calibrated with indium. All the samples (5mg) were 
heated in aluminum pans using dry nitrogen as the 
effluent gas. The analysis was performed with a heating 
range of 20-240 
0
C and at a rate of 10
0
C/minute.
 16 
Stability studies  
The chemical and physical stabilities of NLC 
dispersions were evaluated at 2-8°C for 1 month for its 
clarity, particle size, and drug content. 
PREPARATION OF ETORICOXIB LOADED NLC 
GEL
17, 18
 
Based on the previously mentioned characterizations 
(particle size, entrapment efficiency and in vitro release 
profile of NLC dispersion) NLC formulation with 
optimum physicochemical properties were selected. 
NLC gel was prepared by dispersing carbopol 940 in 
small quantity of distilled water to prepare aqueous 
dispersion, which was then allowed to hydrate for 4 to 5 
hour. Glycerol (10% w/w) was added subsequently to 
the aqueous dispersion and the Lyophilized NLC 
powder equivalent to 1.0% of Etoricoxib was 
incorporated in it. Triethanolamine was added to the 
above dispersion using an overhead stirrer at speed of 
1200 rpm (Remi Motor, India). Stirring was continued 
till the carbopol got dispersed. The gel was allowed to 
stand overnight to remove entrapped air.
 
The NLC gel 
was also prepared by using HPMC by above method. 
Composition of NLC Gel formulation shown in Table 2.
 
2: Composition of NLC Gel formulation 
 
 
 
 
 
 
 
EVALUATION OF NLC GEL 
Physical appearance & Homogeneity 
Physical appearance and homogeneity of gel was 
observed visually. 
Spreadability study of NLC gel 
The spreadability of the gel formulations was 
determined at 24h after preparation, by measuring the 
spreading diameter of 1gm gel between two horizontal 
plates (20 x 20 cm
2
) after 1 minute. The standardized 
weight tied on the upper plate was 220gm. The 
spreadability was calculated by using the following 
formula. 
 
Where S is spreadability, M is weight tied on upper 
slide. L is the length of glass slide, t is time taken.
 19 
In-vitro drug release studies of NLC based gel 
The in vitro release studies were performed using 
modified Franz diffusion cell to evaluate the amount of 
Etoricoxib released from each formulation. Dialysis 
membrane 70 (Hi-Media, Mumbai, India) having pore 
size 2.4 nm and surface area of 3.14 cm
2
. The receptor 
medium was approximately 45 ml and composed of 
phosphate buffer saline (PBS), pH 7.4, and stirred by 
magnetic bar at 700 rpm to avoid different 
concentrations within the acceptor medium and to 
minimize stagnant layers. NLC dispersion (equivalent 
to 1mg of drug) was placed in the donor compartment. 
During the experiments, the solution in receptor side 
Composition 
( % w/w) 
Formulation Code 
NLC-F1G-C NLC-F1G-HPMC 
Carbopol 940P 
Lyophilized NLC 
(NLC eq to 1.0%) 
Glycerin 
Triethanolamine 
Distilled water 
1% 
1.0% 
 
10% 
q.s. 
q.s. 
1% 
1.0% 
 
10% 
q.s. 
q.s. 
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was maintained at 37
0
C±0.5
0
C. After certain time 
interval, 3ml of the sample medium was withdrawn 
from receiver compartment through side tube and same 
volumes of freshly prepared receptor medium were 
added. The samples were analyzed by UV-Visible 
spectrophotometer at 233nm. For each formulation, the 
release studies were performed in triplicate.  
Permeation data analysis 
The permeation profiles were constructed by plotting 
the cumulative amount of Etoricoxib permeated per 
unit dialysis membrane area (µg/cm
2
) versus time. The 
steady state flux (Jss, µg/cm
2
/hr) of Etoricoxib was 
calculated from the slope of the plot using linear 
regression analysis. The permeability co-efficient (Kp) 
of the drug through the membrane was calculated using 
the following equation.
 
 
 
Where, C is the initial concentration of the drug in the 
donor compartment. The penetration enhancing effect 
was calculated in terms of enhancement ratio (Er) by 
using the following equation.
 20
 
 
RESULT AND DISCUSSION 
Solubility profile of Etoricoxib 
The solubility profile of Etoricoxib in phosphate buffer 
of different pH was determined.  It can be seen from 
the Figure 1 that solubility of the drug increased with 
increase in pH up to pH 7.4, and then the solubility 
decreased. The solubility of Etoricoxib in phosphate 
buffers of pH 6.8 and 7.4 at 37
0
C±0.5
0
C after 24h were 
3.088 mg/ml and 8.151 mg/ml respectively. 
 
Figure 1: Solubility Profile of Etoricoxib in different phosphate buffer 
 
Apparent partition coefficient of Etoricoxib 
Determination of partition coefficient of drug is essential 
as it affects entrapment efficiency as well as release of 
drug from the formulation. Isopropyl myristate (IPM) 
was chosen as lipophilic phase in partitioning 
experiment, because its polar and non-polar properties 
can simulate skin lipids.
21
 The apparent partition 
coefficient values in Table 3, indicated an expected 
increase in the lipophilicity of the acidic drug, like 
Etoricoxib, by decreasing the pH value. While at pH 7.4, 
the drug was completely ionized, so the partition 
coefficient decreased. From this study, it was shown that 
Etoricoxib had moderate lipid and aqueous solubility. 
Hence, the drug could be considered as a good candidate 
for transdermal drug delivery system,  as it can be  
soluble in the sebum of the skin, and then readily 
penetrate into the lower skin layers to dissolve in the 
tissue fluids. 
Preparation and Characterization of NLC Dispersion 
The Etoricoxib loaded NLC containing different blends 
of stearic acid and oleic acid (SA+OA) were prepared by 
melt emulsification and low-temperature solidification 
method. In particle sizing technology, span is a measure 
of the poly-dispersity index (PI) i.e. particle 
homogeneity and it varies from 0 to 1. 
 
Table 3: Apparent Partition coefficient of Etoricoxib in PBS 
System Apparent Partition 
coefficient* 
IPM / pH 4 Buffer 22.705 ± 1.20 
IPM / pH 5 Buffer 15.00 ± 0.870 
IPM / pH 6 Buffer 9.35 ± 1.22 
IPM / pH 6.4 Buffer 8.188 ±  0.33 
IPM / pH 6.8 Buffer 5.449 ± 0.52 
IPM / pH 7.0 Buffer 2.598 ± 0.538 
IPM / pH 7.2 Buffer 3.055 ± 0.087 
IPM / pH 7.4 Buffer 2.379 ± 0.557 
IPM / pH 7.6 Buffer 4.206 ± 0.532 
IPM/ Water 24.579 ± 1.46 
*Mean ± S.D 
The d90 for nanoparticulate dispersion determined using 
Malvern Mastersizer showed size ranging from 244 to 
2831 nanometer. NLC-F3 had polydispersity index of 
0.690 indicated homogeneity in particle size distribution 
(Figure 2). The drug entrapment efficiency and drug 
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loading capacity of NLC-F1 & F3 were increased from 
69% to 76% and from 6.45 to 7.06% respectively, on 
increasing the percentage of OA from 10 to 30 wt%. It 
might be due to the incorporation of liquid lipids to solid 
lipids which could lead to massive crystal order 
disturbance, and the resulting matrix of lipid particles 
had great imperfections in the crystal lattice and leaves 
enough space to accommodate drug molecules, thus, 
leading to improved drug loading capacity and drug 
entrapment efficiency. Higher entrapment in formulation 
containing 30% oleic acid also indicates the higher 
solubility of Etoricoxib in oleic acid as compare to 
stearic acid. The particle size distribution, span values, 
%Entrapment efficiency, %Drug loading of NLC are 
presented in Table 4. 
 
Table 4: Particle size distribution of different formulations of NLC and Blank formulation 
Formulation 
code 
 
Mean volume distribution Span Percentage 
Entrapment 
efficiency* 
Percentage Drug 
loading* 
d10% d50% d90% 
NLC-F1 0.129 0.183 11.094 59.91 69.33 ± 0.57 6.48 ± 0.05 
NLC-F2 0.145 0.537 23.528 43.54 72.00 ± 2.00 6.71 ± 0.175 
NLC-F3 0.126 0.171 0.244 0.690 76.33 ± 1.527 7.08 ± 0.132 
B-NLC(Blank) 0.492 0.789 2.831 2.964 - - 
*Mean ± S.D 
                                
 NLC-F1            NLC-F2 
             
NLC-F3      Blank NLC 
Figure 2: Particle size distribution graphs of different formulations of NLC and Blank formulation 
 
Zeta Potential (ζ) 
The zeta potential graph of the NLC dispersion is given 
in Figure 3. The surface charge values are negative for 
empty and drug-loaded samples. Moreover, these values 
are lower in drug-loaded samples than empty e.g. zeta 
potential  of  blank NLC was -12.7 while for  NLC-F1, 
NLC-F2 and NLC-F3 dispersion it was-11.2, -11.9 and -
11.8. The presence of drug causes a diminution of 
surface charge of all the investigated samples. Moreover 
samples have different zeta potential values because the 
surface charge depends on lipid matrix used. The higher 
magnitude of zeta potential indicates the stability of 
formulation.  
Scanning Electron Microscopy 
The micrograph of the NLC-F3 illustrated spherical 
droplets in the nanometer range (Fig. 4). The results 
indicated that the particles were spherical and no drug 
crystal of particles visible in the figure. The picture 
shows agglomeration of particles due to the lipid nature 
of the carriers. Some particle shapes deviates from 
spherical shape due to the lipid modification during the 
drying process of sample treatment. 
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(a)                             (b) 
 
        
(c)       (d) 
Figure 3: Zeta potential of (a) Blank NLC, (b) NLC-F1, (c) NLC-F2 and (d) NLC-F3 Dispersion respectively. 
 
 
Figure 4: SEM of NLC-F3 Dispersion 
Infra-red spectroscopy  
For FTIR study about 1-2 mg of sample were mixed 
with anhydrous potassium bromide. The IR spectra of 
pure drug Etoricoxib, SA, SA+OA, SA+OA+ETORI, 
BLANK NLC, DNLC are shown in Figure 5. The IR 
spectrum of pure drug, Etoricoxib, which is 5-Chloro-6'-
methyl-3-[4-(methylsulfonyl) phenyl]-2, 3’-bipyridine 
shows a peaks at 1592.9 cm−1 (C=N stretching 
vibration), 1430.0, 1299.4, 1136.8, and 1089.6 cm−1 
(S=O stretching vibration) and 834.0, 777.1, and 
639.22009 cm−1 (C–Cl stretching vibration). However, 
in the IR spectrum of Etoricoxib loaded NLC (Figure 5f) 
peaks of CN group and C-Cl group are absent. It is 
evident that the IR spectrum of NLC resembles that of 
the lipid thus proving that the lipid forms the outer core 
and the drug has been successfully incorporated inside it 
.
22 
Thermal analysis 
Differential Scanning Calorimeter Analysis (DSC) 
Differential scanning calorimetry enables the 
quantitative detection of all processes in which energy is 
required or produced (i.e., endothermic and exothermic 
phase transformations).
23
 It is considered as a tool to 
investigate the melting behavior of crystalline materials 
like solid lipid nanoparticles. Main purpose of this test 
was to inspect whether or not the crystallinity was 
different in the lipid nanoparticles compared with the 
raw materials. Blended matrix of lipid shows a melting 
point depression as compared to solid lipid. E.g. melting 
point of stearic acid was 67.81
0
C but mixture of stearic 
acid (70%) and oleic acid (30%) showed a melting point 
depression 58.17
0 
C. DSC thermogram of Etoricoxib 
showed endothermic peak at 136.12°C as evident in 
Figure 6 (a), which is the reported melting point of the 
drug.
24
 Drug loaded NLC in Figure 6 (d), showed a large 
endothermic peak at 58.93°C and disappearance of the 
drug peak suggesting a molecular dispersion of 
Etoricoxib into the loaded NLC and that Etoricoxib 
exists in amorphous state rather than in crystalline state. 
Furthermore, the inclusion of drug molecules in the lipid 
is normally accompanied by a depression in the lipid’s 
melting point.
25, 26 
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Figure 5:  IR spectrum of (a) Etoricoxib, (b) Stearic acid, (c) Stearic acid + oleic acid, (d) Stearic acid + oleic acid 
+ Etoricoxib, (e) BLANK NLC and (f) Etoricoxib loaded NLC respectively. 
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 (a)           (b) 
       
(c)                    (d) 
Figure 6: DSC graph of (a) Etoricoxib, (b) Stearic acid, (c) Stearic acid + oleic acid, (d) Etoricoxib loaded NLC 
respectively. 
Stability study 
After one month refrigerated storage the NLC dispersion 
showed little difference in particle size and entrapment 
efficiency. No obvious change in clarity and degradation 
was observed.  
Centrifugation at 3000 rpm for 30 min also showed that 
the NLC dispersions had a good physical stability 
Preparation and Evaluation of Etoricoxib Loaded 
NLC Gel 
Based on the particle size, entrapment efficiency NLC-
F3 formulation having optimum physicochemical 
properties were selected for preparation of topical gel. 
Lyophilized NLC powder was incorporated into the gel. 
The physical appearance of drug loaded NLC gel was 
found to be off-white in color, smooth in texture and 
translucent. All the formulation was found to be 
homogenous. Formulated gel was also evaluated for 
spreadability study (Table 5).
27
Spreadability means the 
area to which the gel rapidly spread on application to 
skin or affected part of skin. The obtained value 
indicated a good spreadability of formulated gel 
preparations. Spreadability is an essential property for 
topical preparations. A gel application on the inflamed 
skin or diseased skin would be more comfortable if it 
can be spread easily. In general, the gels that possess a 
low consistency index are more spreadable. The release 
of the drug from the formulation is governed by its 
components as well as by the consistency of the 
formulation. 
 
Table 5: Spreadability data of NLC-F3G-C and NLC-F3G-HPMC gels (*Mean ± S.D.) 
 
 
                       
 
 
In vitro release study of NLC gel 
In vitro studies were performed to determine the release 
rate of the drug from the NLC gel formulations. The 
cumulative percentage release of Etoricoxib from NLC 
gel was investigated for a period of 24 hours (Table 6). 
Each sample was analyzed in triplicate. An initial rapid 
drug release was noted in the NLC gel formulation, which 
could result from the time taken by the drug to diffuse 
across the gel. The direct exposure of NLC gel to 
diffusion media and quick release of drug may account 
for initial release in NLC gel. Figure 7 depicts the drug 
release profile of NLC-F3G-C and NLC-F3G-HPMC 
gels.
 
Formulation Code Spreadability* (g.cm/sec) 
NLC-F3G-C 200.174 ± 5.498 
NLC-F3G- HPMC 206.72± 4.466 
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Table 6: Drug release profile of NLC-F3G-C and NLC-F3G-HPMC gels 
S. No. Time 
(hr) 
% Release of drug from NLC gel * 
NLC-F3G-C NLC-F3G-HPMC 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
0.25 
0.50 
1.00 
2.00 
3.00 
4.00 
5.0 
6.0 
8.00 
12.0 
24.0 
4.638±0.750 
5.495±1.586 
6.906±2.069 
10.421±2.245 
13.272±5.634 
15.296±5.176 
18.377±6.128 
23.120±5.837 
28.508±1.602 
65.346±1.944 
87.208±3.735 
3.567±0.650 
4.596±1.686 
5.566±2.168 
8.481±2.234 
9.162±5.830 
18.229±5.287 
20.382±6.245 
26.586±5.837 
30.654±2.136 
58.154±1.879 
79.548±3.456 
*Mean ± S.D. 
 
 
Figure 7: Drug release profile of NLC-F3G-C and NLC-F3G-HPMC gels 
 
Permeation data analysis  
In vitro permeation studies were performed to compare 
the permeation of etoricoxib to the various NLC gel 
formulations i.e. NLC-F3G-C (Carbopol) and NLC-
F3G-HPMC. The permeation study revealed that the 
permeability parameters like steady-state flux (Jss), 
permeability coefficient (Kp), were higher in both 
formulations. The steady-state flux (Jss) for NLC-F3G-
C and NLC-F3G- HPMC were 115.445±0.106 and 
104.830 ±0.101 µg/cm
2
/hr respectively. 
Release order kinetics study 
The release data were fitted to various kinetic models in 
order to calculate the release constant and regression 
coefficients. The kinetic models used were zero order 
equation, first order equation, Higuchi model and 
Korsmeyer-Peppas model. The regression coefficients 
for NLC-F3G-C were 0.920, 0.823, 0.888, and 0.922 
and for NLC-F3G- HPMC was 0.931, 0.761, 0.937, and 
0.936 respectively. The release of drugs from NLC is 
found to be Anomalous (non-Fickian) diffusion 
controlled release. NLC-F3G-HPMC exhibit Anomalous 
(non-Fickian) diffusion, and closely follows Higuchi 
Model and also highly correlated with Korsmeyer-
Peppas model and NLC-F3G- C closely follows 
Korsmeyer-Peppas model and also highly correlated 
with Higuchi Model. 
CONCLUSION 
Nanostructured lipid Carriers were prepared using Melt 
emulsification and low-temperature solidification 
method. FTIR and DSC studies of Etoricoxib, stearic 
acid, oleic acid and their physical mixture confirmed 
that there was no significant interaction between them. 
Absence of melting peak of drug in DSC of formulated 
NLC confirms the change in state of drug from 
crystalline to amorphous form. The Zeta Potential value 
predicted good particle stability because the repulsive 
forces prevent aggregation with aging. In-vitro drug 
release pattern of NLC dispersion gel showed burst and 
control release. Burst release as well as sustained release 
both are of interest for dermal application. Burst release 
can be useful to improve the penetration of drug while 
sustained release supplied the drug over a prolonged 
period of time. 
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